Kim, Albert E. http://orcid.org/0000-0003-2359-6209
Nieblas-Bedolla, Edwin
de Sauvage, Magali A.
Brastianos, Priscilla K. http://orcid.org/0000-0003-4470-8425
Article History
Received: 30 June 2021
Accepted: 15 May 2023
First Online: 24 July 2023
Competing interests
: P.K.B. has consulted for Tesaro, Angiochem, Genentech–Roche, ElevateBio, Axiom Healthcare Strategies, Eli Lilly, SK Life Science, Pfizer, Voyager Therapeutics, Sintetica, MPM Capital Advisers, Advise Connect Inspire, Kazia, CraniUS and Dantari; has received institutional research funding (to Massachusetts General Hospital) from Merck, Mirati, Eli Lilly, BMS, Kinnate and Pfizer; has received clinical trial support (to institution) from AstraZeneca, Eli Lilly, Pfizer, Bristol Myers Squibb, Genentech–Roche, GSK and Merck; and has received honoraria from Merck, Medscape, Pfizer and Genentech–Roche. The remaining authors declare no competing interests.